Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value (VIST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value trades at $70.49 (market cap $7.63B). The key difference: Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value is the larger of the two by market cap, and Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value is trading nearer its 52-week high, Travere Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value for 4 Days on average.
| TVTX | VIST | |
|---|---|---|
Market Cap | $4.88B | $7.63B |
Volume | 1,668,577 | 972,922 |
Sector | Health | Energy |
52-Week High | $67.52 | $79.25 |
52-Week Low | $26.79 | $35.02 |
Typical Hold Time | 0 Days | 4 Days |
Enterprise Value | $5.01B | $10.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Vista Energy (VIST) trades at $69.02, down 0.58% on the day, with strong bullish technical signals from moving averages despite recent earnings misses. The company demonstrates robust fundamentals with 52.72% gross margins and 23.88% net income margins, supported by 32% production growth in Q2 2026. Recent news highlights Peter Thiel's $418 million investment and positive coverage from Seeking Alpha citing 70% EBITDA margins.
The outlook remains positive with 100% analyst buy ratings and $91 consensus price target representing 32% upside. Key risks include consecutive earnings misses, high debt levels, and oil price volatility. The stock offers attractive valuation at 9.08 P/E with strong operational momentum in Argentina's Vaca Muerta basin driving growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value
Vista Energy is an independent oil and gas company focused on exploration, development, and production in Latin America. Its operations are centered on the Vaca Muerta formation in Argentina.
Read more on VIST →
